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In atopic individuals, cutaneous antigen-presenting 
cells (APC), i.e., Langerhans cells and dennal den-
dritic cells, frequently display anti-IgE reactivity. 
Although earlier observations suggested that this 
phenontenon results front the binding of(contplexed) 
IgE to the low-affinity IgE receptor (FcERIIICD23), 
we and others dentonstrated recently that Langer-
hans cells, derntal dendritic cells, and peripheral 
blood ntonocytes front atopic individuals can bind 
ntononteric IgE via the high-affinity receptor for IgE 
(FcERI). These new observations re-stintulated inves-
tigations ainting to unravel the nature and function-
ality of the relevant ill vivo IgE-binding ntoiety(-ies) 
on APC. New data dentonstrate that FCERI, both 
quantitatively and qualitatively, is the pivotal serunt 
T he syndrome of atopy consists of three major symp-toms, i.e., allergic rhinoconjunctivitis, allergic astlU1la, and atopic dermatitis [1], and is usually associated with e levated serum immunoglobulin E (lgE). Whereas the pathogenetic role of allergen-specific 
IgE is clearly established in the case of a.llergic rhinoconjunctivitis 
and a.llergic astlU11a, the manifestation of atopic dermatitis cannot be 
easily expla.ined by the occurrence of type I a.llergic immune 
reactions. In fact, the clinical and histopathologic picture as well as 
the emergence kinetics of atopic eczema roughly follow the criteria 
of delayed-type (type IV) in1l11Une reactions. It is presently unclear 
w hether IgE-mediated (type I) and T -cell-mediated (type IV) 
allergic reactions of atopy are events occurring independently of 
each other or are pathogenetically linked. 
IgE-BINDlNG STRUCTURES ON LANGERHANS CELLS 
AND DERMAL DENDRITIC CELLS 
The first evidence for a possibly causative role of IgE in the 
pathogenesis of atopic dermatitis was derived from studies showing 
that skin from patients with atopic dermatitis harbors IgE+ dendritic 
cells in the epidermis (Langerhans cells) as well as in the dermis 
(dermal dendritic cells) [2,3]. Initial attempts to characterize the 
critical IgE-binding structure on Langerhans cells suggested that 
these cells express the low-affinity IgE receptor (Fc€RIIICD23) 
i/l. 5 i(1I [4] and that this receptor is up-regulated after exposure of 
Langerhans cells to certain cytokines [5]. However, the failure of 
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IgE-binding structure on APC of atopics and, even 
ntore intportant, that FCERI on APC functions as an 
allergen-focusing ntolecule. Thus, it is likely that 
allergens ntay be ntore efficiently taken up, pro-
cessed, and presented to T cells after targeting to 
APC via FCERI as contpared with allergen binding to 
APC in the conventional ntanner. III vivo, FCERI-IgE-
dependent allergen presentation ntay critically lower 
atopic individuals' threshold to ntount allergen-spe-
cific T-cell respoD.ses. This would result in the per-
petuation of allergen-specific IgE production (type I 
reactions) and perhaps even the occurrence ofT -cell-
ntediated, delayed-type hypersensitivity reactions in 
allergen-exposed tissues. ] Invest Derftlatol 104:707-
710, 1995 
specific anti-CD23 monoclonal antibodies (MoAbs) to block en-
tirely IgE binding to Langerhans cells [4], the obvious high affinity 
of tlus IgE-binding structure, and the fact that Langerhans cells of 
both normal and atopic skin are capable of IgE bi.nding [2,6] 
prompted the search for IgE-binding moieties other than CD23. 
Recently, tlus issue was clarified by the demonstration that epider-
mal Langerhans cells and dermal dendritic cells of healthy persons 
bind monomeric IgE via the lugh-affiluty IgE receptor Fc€RI [6-9], 
previously thought to be expressed exclusively on mast cells and 
basoplUls. Recently, our group has shown that the high-affinity IgE 
receptor Fc€RI is the biologically relevant IgE-binding structure on 
epidennal Langerhans cells and dermal dendritic cells in diseased 
atopic SkUl (Klubal R el ai, in preparation). The functional signifi-
cance of Fc€Rl expression on dendritic antigen-presenting cells 
(APC) is only poorly understood but could be sinular to that 
observed for other FcRs on APC, i.e., the binding of monomeric or 
antigen-complexed Ig followed by signal transduction and inter-
nalization of FcR-bound immune complexes [10-12]. More rapid 
progress in this research has been hampered by the relative sparsity 
of these cells and by difficulties in isolating and purifying them from 
tissue samples. Tlus problem may soon be circumvented by exper-
imental protocols allowing the i/l I/ilro generation of Langerhans-
cell-like dendritic cells from the pool of CD34-expressing stem 
cells from cord [13] and peripheral blood (Strunk D e/ ti l, submit-
ted) or by the cyto1..-ine-driven expansion of FC€RI-expressing 
dendritic cells from as yet poorly characterized CD34-negative 
precursor cells present in human peripheral blood [14,15]. In the 
meantime, a valuable experimental tool for the investigation of 
Fc€lU function on APC was gained by our recent finding that 
Langerhans cells are not the only APC capable ofFC€RI expression. 
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IgE-BINDING STRUCTURES ON 
MONOCYTES/MACROPHAGES 
Unti l recently, it was gen erally believed that monocytes/macro-
phages express only low- affin ity 19E binding sites, i.e ., the inducible 
form of the low-affinity 19E receptor CD23 [1 6] and the IgE-
bindiJlg protein EBP [17]. T hi s led to the assumption that these cell 
types preferentially bind preformed 19E complexes rather than 
monomeric IgE. We have found recently that monocytes of atopic 
individuals can bind monomeric 19E and that tlus binding occurs via 
FCEIU [18]. [n particular, monocyte FCERI expression was detected 
in most patients with atopic dermatitis (70% to 80%) and in a 
proportion of those with allergic r1unoconjunctivitis (approximate-
ly 50%). However, this demonstration of FCERI on monocyte 
surfaces does not exclude the possibility that, under ;/1. villo condi-
tions, the binding of polyclona l serum IgE to m onocytes occurs 
predomin antly via FCElU1 or EBP. We have addressed tlUs issue 
experimentally and have fOUJld that freshly isolated monocytes of 
atopics, but not of no na topics, carry cell-surface-bound IgE i ll IIivo 
and that the majority of1gE-binding sites are occupied by (elevated) 
serum IgE (Maurer D et ai, submitted). The further observation that 
lactic acid treatment but not lactose treatment of the ceLIs almost 
completely removed i/l. IIillo-bound IgE molecul es argued against a 
possible role of EBP in thi s process, but did not exclude an 
important ro le for CD23 as a relevant IgE-binding molecule ill IIillo. 
For tlus purpose, we exposed lactic- acid-treated monocytes to sera 
from birch-pollen-sensitized individuals, e ither in the presence or 
absence of inhibiting MoAbs to FeERI o r CD23 , and visualized the 
binding of birch-pollen-specific serum IgE by a subsequent incu-
bation step with biotinylated recombinant Bet v I, the m ajor 
birch-po llen allergen. T he MoAb to FCERI selectively abolished the 
binding of polyclonal serum IgE to monocyte surfaces (Maurer D 
ct ai, submitted). T hese resul ts indicate that, in analogy to Langer-
hans cells, monocytes of allergic individuals carry FCElU-bound, 
allergen-specific IgE ill vivo and that the interaction with polyvalent 
allergen is fo ll owed by the triggering of FcElU rather than CD23. 
STRUCTURAL AND FUNCTIONAL ANALYSIS OF FCElU 
ON APC 
On basophil s and mast cells, FCERI is expressed as a tetrameric 
holoreceptor composed of one a - chain, one ,B-chain, and one 
'Y-chain homodimer [10]. Mol ecular and biochemical studies have 
revealed that Langerhans cells [6,7] and monocytes of atopic 
persons [18] co-express the IgE-binding FcElU a-chain and the 
signal-transducing FCElU'Y-chain at both th e mRNA and protein 
levels and that the monocyte FCEIUa and FCERI'Y prote in chaiJls are 
physica lly associated and thereby form functional FCERI complexes 
(Fiebiger E, unpublished observations). For reasons yet unknown, 
o ur attempts to detect FeElU,B mRNA and protein in Langerhans 
cells and monocytes have so far been unsuccessful [6 ,18]. Apart 
/Tom procedural considerations, it is possible that the lugh-a ffinity 
IgE receptor on APC consists of a - and 'Y-chains only. In fact, 
transfection experiments have shown that this chain composition 
suffices for functiona l cell-surface expression of the hum an receptor 
[19,20.1. However, the COOH-terminal intracytoplasmic portion 
of the ,B-chain has been found to contain a conserved protein 
sequence motif (antigen recognition activation motif) [21] , which 
allows the physica l association w ith members of the src protein 
tyrosine kinase (PTK) fa mily. Accordin gly, recent findings have 
re-emphasized an eminent functional importan ce of the ,B-subunit, 
showing that the constitutive ly ,B-associated src PTK Iyn is crucial 
for phosphorylation and activation of the FeERI'Y subunit. FCEIU'Y 
thus modified can then activate the PTK syk and initiate further 
downstream signaling events, i.e., phosphorylation and activati'on 
of phosphol ipase C-YI' breakdown of phospho i.nositols, and eleva-
tion of the cytosolic calcium concentration [22] . Despite the 
apparent lack of,B, FeERI on APC is capa ble of m ediating PTK 
activation [23] and ca lcium mobilization [1 8,23] , indicating com-
petent signaling via tlus receptor. At the moment, it is tempting to 
THE JOURNAL OF INVESTIGATIVE DER.MATOLOGY 
spec ulate about the presence of a putative ,B-like structure that 
functionally substitutes for the "classic" FCElU,B-chain in APC. 
BIOLOGIC CONSEQUENCES OF ALLERGEN-IgE BINDING 
TO FcElU ON APC 
T he binding of all ergen-specifi c IgE to FCElU on mast ceLIs and 
basopluls, followed by bridging of the membrane-bound IgE 
molecules by soluble, multivalent allergens, results in cellul ar 
degranulation and consequ ently in the release of proinflammatory 
substances such as histamine, serotonin, prostaglandins, and leuko-
trienes [24 -26], as well as in the synthesis and secre tion of 
cytokines such as interleukin (IL)-3 , IL-4, IL-5, 1L-6, granulocyte-
macrophage colony-stimulating factor, and interferon-'Y [27-29]. 
Because FCElU on APC constitutes a fun ctional cell-surface recep-
tor and APC are potent producers of cytokin es [30-34] and 
eicosanoids [35,36] , it is Likely that FCElU induces the release of 
biologic effector molecules by APC and critically modulates or even 
initiates allergic inflammatory responses in allergen-exposed tissues. 
We recently found that, besides its putative cytokine-inducing 
properties, FCEIU on professional APC fun ctions as an allergen-
focllsing receptor structure. U sing sera from grass- or birch-polJen-
sensi tized donors and recombinant birch (rBel v I) and grass pollen 
(rPhl l' II) allergens as well as h apten (hydrox Y-lutrophenacetyl, 
NP)-specific. monomeric 19E (cIgE) and NP-conjugated allergens, 
we observed that the presence of cell-surface- bound IgE results in 
efficient alle rgen binding to the monocytes of atopics . Mo Ab-
bloc king experiments revealed that FcdU, rather than FCElUI, is 
the pivotal moiety that mediates this event. Even more important, 
cIgE-mediated allergen binding to monocyte-enriched, peripheral 
blood mononuclear cells of atopic persons resulted in a 100-1000-
fold amplifica tion of rBet " I or rPhi p II presentation to autologous 
T -cell clones with peptide specificities for B el v I or Phi p II. The 
addition of the anti-FcEIUa-chain MoAb, but not of an anti-CD23 
MoA b, reduced tlus cIgE-enhanced, allergen-specific T-celJ-c1one 
response to levels seen in the absence of cIgE. T his demonstrates 
that FCERI, but not FCElUI, m ediates IgE-dependent allergen 
uptake, processing, and presentation by professiona l APC fi·om 
atopics (Maurer D el ai, subnutted). Thus, our findings emphasize 
an ;;IS yet unkJlown fun ctio n of FCElU in atopic diseases and provide 
c1e;;l r evidence that the presence of thjs receptor on APC critically 
Im,vers the threshold of atopic individual s to mount alJergen-
specific T - cell responses . 
With regard to IgE-mediated cutaneous allergy, these findings 
may have pathogenetic sigluficance for de layed-type atopic inflam-
mation occurring in the skin and, perhaps, in other ti ssues. If 
repeated alJergeluc exposure of the skin and/or mucosal tissue 
resll lts in the production of allergen-specific IgE (Fig 1A), then the 
inte raction of allergen with IgE bound to FcElU on skin APC may 
reslllt in IgE-facilitated alle rgen presentation to T cells in lymphoid 
and non-lymphoid organs and, furth ermore, in allergen/ lgE-
dependent activation and cytokine secretion by FCEIU-expressing 
cells within the tissue (Fig 1B). Tn particular, monocytic cells 
secJ"ete IL- 1 and tumor necrosis factor-a after cross-linking of 
cell-surface-bound IgE moieties il/. "it yO [34]. These two cytokines 
have been shown to play an indispensable role in the e lkitation of 
cutaneous late-phase atopic reactions [37,38]. IL- l and tumor 
nec rosis factor-a exert some of their biologic efFects via induction 
of :E- selectin , vascular cell adhesion molecule-I, and intercellu lar 
adhesion molecule-1 expression by endothelia l cells (37,39]. Up-
regulated endothelial cell adhesion molecules promote and rein-
force leukocyte-endothelial-cell interactions and, therefore, are a 
prerequisite for transmigration of inflammatory ceLIs into inflam ed 
tissue [40]. In delayed-type atopic reactions, the latte r event is 
ch ;;l racte rized by extravasation of (Fc-IgE receptor-bearing) eosi-
nopillis and macroph ages, as w ell as by a pronounced accumulation 
ofT lymphocytes [3]. At this particular step, IgE-amplified allergen 
presentation by FaRl-expressing skin APC m ay decisively control 
the qu a]jty and quantity of allergic tissue inflammation . Even in the 
presence of minute allergen concentrations, tlus mechanism may 
allow effective ac tivation and clonal expansion of skiJl - infiltrating, 
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Figure 1. Hypothetical model of pathogenetic mechanisms oper-
ative in cutaneous delayed- type atopic inflammation. A, rep eated 
allergen exposure and genetic factors are implicated in the preferential 
expansion of allergen-specific ThO cells and in their conversion into 
Th2-like cells. As a consequence, allergen-specific B cells differentiate into 
plasma cells that produce allergen-specific 19E. B, Upon allergen re-
exposure, 19E-bound skin APC (Langerhans cells and other dermal den-
dritic cells) may be directly activated by allergen-mediated cross-linking of 
their high-affinity 19E receptors (FceRl) . T lus may be followed b y the 
induction of cytokine production and secretion and, as a consequence, may 
result in increased expression of adhesion molecules 011 dermal endothelial 
cens and in the influx of eosinoplUls and T cells. On the other hand, even 
in the presence of minute allergen concentrations, FcelU-mediated ampli-
fication of allergen presentation may result in the effi cient activation of 
allergen-specific Th2 cells, wluch cause anergic tissue inflammation due to 
cytokine release. 
allergen-specific T helper cells, with a Th2-like cytokine secretion 
pattern [41-43] and with the capacity of m ediating (IL-4-depen-
dent) allergic tissue reactions [44]. Moreover, activated allergen-
specific Th2-like cells should possess the capability to promote B 
cells to secrete allergen-specific IgE, which again binds to Fo:RI-
expressing APC in skin and other tissues. If this allergen-driven , 
self-amplifying mechanism is operative in atopic diseases ill vivo, 
then therapeutic strategies should aim to interrupt tlus viciolls circle 
by interference with FcElU expression, IgE binding to FceRI , 
and/or FceRI-mediated signal transduction by APC. 
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